Literature DB >> 45434

5,7-dihydroxytryptamine lesions of dorsal and median raphé nuclei and performance in the social interaction test of anxiety and in a home-cage aggression test.

S E File, J R Hyde, N K MacLeod.   

Abstract

Micro-injections of the neurotoxin 5,7-dihydroxytryptamine into the dorsal raphe nucleus produced a behavioural profile in the social interaction test of anxiety similar to that seen in rats treated chronically with benzodiazepines. Neurotoxin injections into the median raphé nucleus did not produce a profile significantly different from that of the controls. In the control rats and in the rats with lesions of the median raphé nucleus, ACTH1-24 (corticotrophin) significantly reduced active social interactions, whereas it was without effect on the rats with lesions of the dorsal raphé nucleus. In the home-cage intruder test, the median raphé-lesioned rats submitted less to the intruder and stood and jumped on him more often than did the controls. The dorsal raphé-lesioned rats showed significantly fewer interactions of all kinds, compared with control rats when an intruder was placed in their home cages.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 45434     DOI: 10.1016/0165-0327(79)90030-2

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  12 in total

1.  Pharmacological depletion of serotonin in the basolateral amygdala complex reduces anxiety and disrupts fear conditioning.

Authors:  Philip L Johnson; Andrei Molosh; Stephanie D Fitz; Dave Arendt; Gerald A Deehan; Lauren M Federici; Cristian Bernabe; Eric A Engleman; Zachary A Rodd; Christopher A Lowry; Anantha Shekhar
Journal:  Pharmacol Biochem Behav       Date:  2015-11       Impact factor: 3.533

2.  Effect of lithium on behavioral disinhibition induced by electrolytic lesion of the median raphe nucleus.

Authors:  Fernanda A Pezzato; Adem Can; Katsumasa Hoshino; José de Anchieta C Horta; Miriam G Mijares; Todd D Gould
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

3.  Proceedings of the Fiftieth Anniversary Meeting of the British Pharmacological Society, University of Oxford, 16-18 September 1981. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1981-12       Impact factor: 8.739

4.  Effect of serotonergic lesion on "anxious" behaviour measured in the elevated plus-maze test in the rat.

Authors:  M Briley; P Chopin; C Moret
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Induction of aberrant agonistic behavior by a combination of serotonergic and dopaminergic manipulation in rats.

Authors:  Nobuyuki Kai; Shuichi Ueda
Journal:  Brain Struct Funct       Date:  2021-02-24       Impact factor: 3.270

6.  Depletion in amygdaloid 5-hydroxytryptamine concentration and changes in social and aggressive behaviour.

Authors:  S E File; T A James; N K MacLeod
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Activation of kappa opioid receptors in the dorsal raphe have sex dependent effects on social behavior in California mice.

Authors:  Emily C Wright; Tiffany V Parks; Jonathon O Alexander; Rajesh Supra; Brian C Trainor
Journal:  Behav Brain Res       Date:  2018-06-07       Impact factor: 3.332

8.  The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats.

Authors:  C H Cheng; B Costall; J Ge; R J Naylor
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

9.  Potential anxiolytic properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin 1A receptor agonist.

Authors:  M Carli; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

10.  Neuroanatomical sites of action of 5-HT3 receptor agonist and antagonists for alteration of aversive behaviour in the mouse.

Authors:  B Costall; M E Kelly; R J Naylor; E S Onaivi; M B Tyers
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.